Remibrutinib exhibits long-term favorable safety profile for chronic spontaneous urticaria
SAN ANTONIO — Remibrutinib displayed sustained efficacy for chronic spontaneous urticaria with a favorable safety profile over 52 weeks, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.“Treating these patients has a huge, huge impact on the patient’s well-being and quality of life,” Warner W. Carr, MD, FACP, FACAAI,
Source: healio.com